People and Business News — 9/22
People News
Clinovo appointed Nandish Poluru as Chief Executive.
Allucent, announced the appointment of Steffany Cox as its chief marketing officer.
Susan Robbins joined HeartcoR Solutions as its director of training. Additionally, Michelle Mills has joined the organization as director of ECG analysis and quality control.
MMS Holdings Inc. announced the appointment of Kelly J. Hill to Chief Strategy Officer.
Florence Healthcare has hired Kristin Surdam, who will lead the company’s thought leadership team and efforts to engage sponsors and contract research organizations, and Gunnar Esiason, who will lead patient-facing strategies.
Elligo Health Research announced Chief Scientific Officer Rebecca Kush, PhD, was recently elected Chair of the Vulcan Advisory Council.
Promontory Therapeutics Inc. announced the appointments of Helene Shea, PhD, as Vice President of Chemistry, Manufacturing and Controls, and Kate Hogg Call as Vice President of Clinical Operations.
Parexel promoted Peyton Howell to the newly created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence.
Business News
Strata Oncology, Inc. announced that Sarah Cannon Research Institute (SCRI) has joined the Strata Precision Indications for Approved THerapies (Strata PATH) trial.
Recognition
Jumo Health announced it has made Inc. Magazine’s Inc. 5000 list.
LaQuinta Jernigan, Chief Operating Officer for mdgroup, has been recognized as one of 100 most inspiring people in life sciences.
WCG’s Vice President, Patient Advocacy and Clinical Research Diversity, Lori Abrams, has been named a Diversity, Equity, and Inclusion Champion.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
